GYRE THERAPEUTICS INC (GYRE)
Health Care · Antifibrotic biopharmaceuticals · NASDAQ
A China-based biopharmaceutical company generating revenue from approved antifibrotic treatments while advancing late-stage candidates for liver and other organ fibrosis in the U.S. market.
What GYRE THERAPEUTICS INC does
Gyre Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for organ fibrosis and inflammatory diseases. The company operates through a majority-owned subsidiary in China (Gyre Pharmaceuticals) where it commercializes antifibrotic products including ETUARY® (pirfenidone) and Etorel® (nintedanib) for pulmonary fibrosis, and Contiva® (avatrombopag) for hematologic conditions. In the U.S., the company is advancing late-stage clinical candidates such as F351 (Hydronidone) for liver fibrosis, with plans to leverage its established China commercial base to support pipeline advancement.
Themes: ["Organ fibrosis / antifibrotic therapies","Pulmonary fibrosis","Liver fibrosis","Small-molecule therapeutics","China-focused commercial platform"]
Fundamentals
- Price$6.86 as of 2026-07-09 close
- Market cap$760M as of 2026-07-10
- 1-year return-14.3% as of 2026-07-09 close
- P/E151.25 as of 2026-07-10
- Net margin-5.4% as of 2026-07-10
- Gross margin+95.1% as of 2026-07-10
- ROE-6.3% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+16.3% as of 2026-07-10
- Revenue CAGR (3y)+4.5% SEC XBRL
- Beta2.35 as of 2026-07-10
Dividend: 1-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Clinical development risk: F351 (Hydronidone) advancement depends on successful clinical trials; failure to demonstrate efficacy or safety could delay or prevent commercialization in the U.S.","Regulatory and reimbursement risk: Product access and pricing in the PRC are subject to government controls and National Reimbursement Drug List inclusion, which could impact ETUARY® sales and market position.","Merger integration risk: The pending Cullgen merger creates execution risk and may distract from core operations; failure to successfully consummate or integrate the transaction could impact the company's growth strategy."]
Competitors & peers
- Boehringer Ingelheim (nintedanib/Ofev)
- Roche/Genentech (pirfenidone/Esbriet)
- Galera Therapeutics
- Galapagos (nintedanib)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.